

ASSIGNMENT

WHEREAS We, the below-named inventors (hereinafter referred to as Assignors), of an invention entitled:

ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

as disclosed and claimed in the applications identified below this paragraph:

Application Number	Country of Filing	Filing Date
62/932,373	US	November 7, 2019

and as disclosed and claimed in an application to be filed under the Patent Cooperation Treaty, claiming priority from United States Provisional Application No. 62/932,373, filed November 7, 2019,

AND, whereas We authorize and request a patent practitioner of record in this application to insert the International Application Number and filing date of the above-referenced application in the table below when known:

Application Number	Country of Filing	Filing Date
	PCT	

WHEREAS, Eisai R&D Management Co., Ltd., a corporation of Japan, whose post office address is 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo, Japan 112-8088 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, We, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and We hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, issue all Letters Patent for this invention to Assignee, or its successors and assigns, in accordance with the terms of this Assignment;

AND, We covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;

AND, We further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, We have hereunto set our hands.

ASSIGNOR (Inventor) 1

Signature

Earl F. ALBONE

Print Name

5 November 2020

Execution Date

ASSIGNOR (Inventor) 2

Signature

Jared SPIDEL

Print Name

Execution Date

ASSIGNMENT

WHEREAS We, the below-named inventors (hereinafter referred to as Assignors), of an invention entitled:

ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

as disclosed and claimed in the applications identified below this paragraph:

Application Number	Country of Filing	Filing Date
62/932,373	US	November 7, 2019

and as disclosed and claimed in an application to be filed under the Patent Cooperation Treaty, claiming priority from United States Provisional Application No. 62/932,373, filed November 7, 2019,

AND, whereas We authorize and request a patent practitioner of record in this application to insert the International Application Number and filing date of the above-referenced application in the table below when known:

Application Number	Country of Filing	Filing Date
	PCT	

WHEREAS, **Eisai R&D Management Co., Ltd.**, a corporation of Japan, whose post office address is 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo, Japan 112-8088 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, We, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and We hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, issue all Letters Patent for this invention to Assignee, or its successors and assigns, in accordance with the terms of this Assignment;

AND, We covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;

AND, We further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, We have hereunto set our hands.

ASSIGNOR (Inventor) 1

Signature

Earl F. ALBONE

Print Name

Execution Date

ASSIGNOR (Inventor) 2


Signature

Jared SPIDEL

Print Name

05 Nov 2020

Execution Date